Table 2.
List and characteristics of 17 eligible studies from 2005 to 2022.
| Authors | Publication year | Region | Study design | Sample size | Case | Prevalence (95% CI) | CM prevalence (95% CI) | SCM prevalence (95% CI) | Diagnosis method used | Quality assessment |
|---|---|---|---|---|---|---|---|---|---|---|
| Biffa et al. | 2005 [34] | SNNPR | CS | 974 | 340 | 34.9 (28.7, 40.9) | 11.9 (7.7, 16.9) | 23.0 (13.6, 26.8) | P, B, and CMT | 5 |
| Almaw et al. | 2008 [20] | Amhara | CS | 351 | 14 | 3.9 (0.82, 7.17) | 1.4 (0.9, 3.2) | 2.5 (1.3, 4.9) | P, B, and CMT | 4 |
| Mekibib et al. | 2010 [26] | Oromia | CS | 107 | 76 | 71.0 (65.7, 79.3) | 22.4 (18.2, 27.0) | 48.6 (44.8, 55.3) | P, B, and CMT | 5 |
| Moges et al. | 2011 [35] | Amhara | CS | 322 | 105 | 32.6 (27.5, 37.8) | 0.9 (0.2, 1.8) | 31.67 (23.2, 36.6) | P, B, and CMT | 4 |
| Abera et al. | 2012 [27] | Oromia | CS | 422 | 75 | 37.1 (33.3, 38.7) | 8.6 (4.2, 12.7) | 28.6 (23.4, 34.8) | P, B, and CMT | 5 |
| Yohannis & Molla | 2013 [28] | SNNPR | CS | 349 | 103 | 29.5 (24.7, 34.3) | 2.6 (0.9, 4.3) | 26.9 (22.2, 31.6) | B and CMT | 6 |
| Musse et al. | 2014 [36] | Addis Ababa | CS | 346 | 169 | 48.8 (44.2, 54.8) | 10.9 (6.3, 15.7) | 37.9 (33.8, 38.4) | B and CMT | 5 |
| Abebe et al. | 2016 [37] | SNNPR | CS | 529 | 331 | 62.6 (58.3, 66.7) | 3.4 (0.5, 7.6) | 59.2 (54.6, 64.8) | P, B, and CMT | 6 |
| Herago et al. | 2017 [29] | SNNPR | CS | 320 | 84 | 26.3 (21.4, 31.1) | 3.7 (1.8, 6.9) | 22.5 (18.3, 27.3) | B and CMT | 5 |
| Mulshet et al. | 2017 [38] | Addis Ababa | CS | 390 | 192 | 49.2 (45.5, 58.7) | 10.2 (7.3, 13.9) | 39 (35.3, 45.8) | B and CMT | 4 |
| Tassew et al. | 2017 [39] | B/Gumuz | CS | 384 | 151 | 39.3 (34.7, 43.5) | 11.5 (7.2, 16.4) | 27.8 (21.3, 31.8) | B and CMT | 5 |
| Birhanu et al. | 2017 [40] | Oromia | CS | 262 | 105 | 40.1 (34.8, 46.3) | 11.2 (7.4, 16.2) | 28.9 (23.8, 33.5) | B and CMT | 4 |
| Etifu & Tilahun | 2019 [30] | SNNPR | CS | 111 | 81 | 73.0 (67.2, 83.5) | 16.2 (12.5, 20.8) | 56.8 (52.6, 63.9) | P, B, and CMT | 6 |
| Abebe et al. | 2020 [31] | SNNPR | CS | 686 | 372 | 54.2 (50.5, 57.9) | 48.1 (44.3, 55.8) | 29.4 (24.6, 34.2) | P, B, and CMT | 5 |
| Assefa | 2021 [41] | Oromia | CS | 126 | 36 | 28.6 (23.5, 32.7) | 23.8 (13.7, 27.4) | 4.8 (2.8, 8.4) | P, B, and CMT | 4 |
| Fesseha et al. | 2021 [32] | Oromia | CS | 384 | 283 | 73.7 (67.1, 83.2) | 21.4 (17.5, 26.2) | 52.3 (45.4, 63.7) | P, B, and CMT | 4 |
| Kidanu | 2022 [42] | Amhara | CS | 375 | 146 | 39.0 (33.3, 42.8) | 9.0 (6.1, 12.7) | 30 (25.4, 35.8) | P, B, and CMT | 6 |
CS: cross-sectional, CM: clinical mastitis, SCM: subclinical mastitis, P: physical, B: bacteriological, CMT: California Mastitis Test, SNNPR: Southern Nations, Nationalities, and Peoples' Region.